evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,359 questions · 2,491 findings · 249 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 696 · 27.9%GRADE not reported 213 · 8.6%Very low 611 · 24.5%Low 595 · 23.9%Moderate 315 · 12.6%High 61 · 2.4%

Antibiotics vs control

Ocular chlamydia trachomatis infection · people (any age) with active trachoma

Antibiotic showed no clear difference in ocular C trachomatis infection Positive test for C trachomatis… compared with control (low certainty).

1 finding from 1 review

Antibiotics vs control

Antibiotic resistance · people (any age) with active trachoma

The review found no eligible studies for this question.

1 finding from 1 review
  • Antibiotics for trachoma 2019 · Cochrane Headline outcomes only
    no estimate extracted
    Studies not reported
    No studies found

Antibiotics vs control

Adverse effects · people (any age) with active trachoma

Antibiotic may leads to lower adverse effects compared with control (low certainty).

1 finding from 1 review

Oral vs topical antibiotics

Antibiotic resistance · people (any age) with active trachoma

The review found no eligible studies for this question.

1 finding from 1 review
  • Antibiotics for trachoma 2019 · Cochrane Headline outcomes only
    no estimate extracted
    Studies not reported
    No studies found

Oral methotrexate and oral prednisone vs prednisone or placebo

Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).

Oral methotrexate and oral prednisone may leads to higher primary outcome: Global improvement of disease activity or damage… compared with placebo and oral prednisone (low certainty).

1 finding from 1 review

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with medium‐dose UVA‐1 phototherapy (50 J/cm²) (low certainty).

1 finding from 1 review

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

The review found no eligible studies for this question.

1 finding from 1 review

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).

1 finding from 1 review

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

The review found no eligible studies for this question.

1 finding from 1 review

Oral methotrexate and oral prednisone vs prednisone or placebo

Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).

Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).

1 finding from 1 review

Medium‐dose UVA‐1 phototherapy (50 J/cm²) vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Medium‐dose UVA‐1 phototherapy (50 J/cm²) showed no clear difference in primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).

1 finding from 1 review